SPR Therapeutics
SPR Therapeutics is a privately held medical device company, providing patients with a non-opioid, minimally invasive pain treatment option. Our SPRINT® PNS System fulfills a critical unmet need for a drug-free, surgery-free option for millions who suffer from chronic pain. Backed by the largest body of clinical evidence in peripheral nerve stimulation for the treatment of pain SPR has demonstrated commercial demand in untapped peripheral (shoulder and knee) and back pain markets and built an incredibly strong foundation for commercial growth. Headquartered in Cleveland, OH with satellite offices in Chapel Hill, NC and Minneapolis, MN, SPR's Senior Management team includes experienced industry veterans with nearly 200 years of collective pain market and MedTech expertise, all driven by our purpose – to improve the quality of patients' lives by providing them with a minimally-invasive, drug-free, surgery-free solution to manage their acute and chronic pain. Sustained Pain Relief Starts Here™ The SPRINT® PNS System, by SPR® Therapeutics, marks an innovative shift in the treatment of pain. Our breakthrough, 60-day treatment is a First-Line™ PNS option uniquely proposed to recondition the central nervous system to provide significant and sustained relief from chronic pain — without a permanent implant, nerve destruction or the risk of addiction. The system has been studied extensively for low back pain, shoulder pain, post-amputation pain, and chronic and acute post-operative pain, and is cleared for use up to 60 days. Recognized by leading pain management centers, this breakthrough neuromodulation treatment offers a patient-preferred alternative to more invasive options. Learn more about the SPRINT PNS System here: https://www.sprtherapeutics.com/physicians/sprint-pns-system/
Work at SPR Therapeutics in HR or recruiting? Claim this page
Headcount trend
SPR Therapeutics went from 285 employees in Oct 2024 to 344 in Sep 2026. Apr to Sep 2026: 20 people joined, 9 left.
Funding rounds
| Date | Round | Money raised | No. | Investors |
|---|---|---|---|---|
| Jan 2024 | Debt Financing | $60M | 1 | |
| Jan 2024 | Series D | $25.6M | 3 | |
| Oct 2021 | Series D | $37M | 3 | |
| Mar 2019 | Series B | $5M | – | – |
| Jan 2019 | Series C | $8M | – | – |
| Oct 2018 | Funding | $10M | – | – |
| Sep 2017 | Series C | $25M | 1 | |
| Feb 2016 | Debt Financing | $1.9M | – | – |
| Aug 2015 | Funding | $1.6M | – | – |
| Jan 2013 | Series A | $5M | 2 |
Org structure
Headcount by department
Peer reviews
Worked with someone at SPR Therapeutics?
Anonymous peer reviews on OffTheRecord
Similar companies
Hiring now
SPR Therapeutics FAQ
How many employees does SPR Therapeutics have?
SPR Therapeutics has about 344 employees, unchanged over the 3 months to Sep 2026.
What is SPR Therapeutics's revenue per employee?
SPR Therapeutics makes about $16K in revenue per employee, based on $5.5M annual revenue and 344 employees.
How much funding has SPR Therapeutics raised?
SPR Therapeutics has raised $179.17M in total funding; its latest round was Debt Financing in Jan 2024.
Data from Company Prospectus, DOL LCA disclosures, WARN notices and 6figr salary profiles.